The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 3038-3046

  Paterson, Alexander H G ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; INDOMETACIN; PAMIDRONIC ACID; PROSTAGLANDIN INHIBITOR; RISEDRONIC ACID; TAMOXIFEN;

BONE ATROPHY; BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; MYELOMA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 0034659915     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<3038::aid-cncr21>3.0.co;2-v     Document Type: Conference Paper

References (62)

1. Milas L, Tofilon P. Tumour metastasis: biology and experimental therapeutic approaches. In: Paterson AHG, Lees AW, editors. Fundamental problems in breast cancer. Martinus Hijhof Publishing, 1987.
2. Orr FW, Varani J, Gondetz MD, Ward PA, Mundy RR. Chemotactic responses of tumour cells to products of resorbing bone. Science 1979;203:176-9.
3. Wicha MS, Liotta LA, Vonderhaar BK, Kidwell WR. Effects of inhibition of basement membrane collagen deposition on rat mammary gland development. Dev Biol 1980;80:253-66.
4. Mundy RR. Bone resorption and turnover in health and disease. Bone 1987;8(Suppl 1):S9-S16.
5. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer 1997;80(Suppl 8):1538-45.
6. Mundy GR. Hypercalcemia of malignancy revisited. J Clin Invest 1988;82:1-6.
7. Berruti A, et al. Pamidronate administration improves the secondary hyperparathyroidism due to "bone hunger syndrome" in a patient with osteoblastic metastases from prostate cancer. Prostate 1997;1:252-5.
8. Kanis JA, Percival RC, Yates AJP, Urwin GH, Handy NAT. Effects of diphosphonates in hypercalcemia due to neoplasia. Lancet 1986;i:615-6.
9. Paget J. The distribution of secondary growths in cancer of the breast. Lancet 1889;i:571-3.
10. Kamenor B, Kieran MW, Barrington-Leigh J, Longenecker BM. Homing receptors as functional markers for classification, prognosis, and therapy of leukaemia and lymphomas. Proc Soc Exp Biol Med 1984;177:211-9.
11. Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940;112:138.
12. Smith R, Jiping W, Bryant J, et al. Primary breast cancer as a risk factor for bone recurrence: NSABP experience. Proc Am Soc Clin Oncol 1999;18:Abstract 457.
13. Paterson AHG. Natural history of skeletal complications of breast cancer, prostate cancer and myeloma. Bone 1987; 8(Suppl. 1):S17-S22.
14. Kanis JA, McCloskey EV, Powles T, Paterson AHG, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:1179-81.
15. Valentin-Opran A, Edouard C, Charhon S, Meunier P. Histomorphometric analysis of iliac bone metastases of prostatic origin. In: Symposium CEMO III, bone and tumours. Geneva Editions, Medicine and Hygiene, 1980: 24-8.
16. Jacobs SC, Lawson RK. Mitogenic factor in human prostate extracts. Urology 1980;16:488.
17. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997;80(Suppl. 8):1581-7.
18. Elomaa I, Blomqvist C, Porrka L, Lamberg-Allardt C, Bergstrom GH. Treatment of skeletal disease in breast cancer: a controlled clinical trial. Bone 1987;8(Suppl 1):S53-S56.
19. van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, Hermans J, Kroon HM, Harinck HI, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonates (APD) treatment. Lancet 1987; 11:983-5.
20. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
21. McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S, et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 1993;3:138-47.
22. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxy-propylidene)-1, 1-bisphosphonate (APD). Br J Cancer 1988;58:621-5.
23. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14:2552-9.
24. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19, Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91.
25. Delmas PD. The use of clodronate in multiple myeloma. Bone 1991;12(Suppl 1):S31-S34.
26. Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 1993;66:141-6.
27. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334:488-93.
28. Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostate cancer. Recent Results Cancer Res 1989;116:567-72.
29. Vorruether R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostate cancer. Br J Urol 1993;72:792-5.
30. Fernandex-Conde M, et al. Skeletal response to clodronate in prostate cancer with bone metastases. Am J Clin Oncol 1997;20:471-6.
31. Ernst DS, MacDonald N, Paterson AHG, Jenson J, Brasher P, Bruera E. A double-blind crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1992;7:4-11.
32. Ernst DS, Brasher P, Hagen N, Paterson AHG, MacDonald N, Bruera E. A randomized, controlled trial of intravenous clodronate in metastatic bone disease and pain. J Pain Symptom Manage 1997;13:319-26.
33. van Holten-Verzantvoort AT, Zwinderman AH, Aaronson NK, Hermans J, van Emmerik B, van Dam FS, et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991;27:544-9.
34. Selander KS, Monkkonen J, Karhukorpi EK, Hardonen P, Hannuniemi R, Vaananen HK, et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-38.
35. Shipman CM, Rogers MJ, Apperley JF, Russel RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98:665-72.
36. Goldhirsch A, Gelber RD, Price KN, Castiglione M, Coates AS, Rudenstam CM, et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994;343: 377-81.
37. Powles TJ, McCloskey E, Paterson AHG, Ashley S, Tidy A, Kanis JA. Oral clodronate will reduce the loss of bone mineral density in women with primary breast cancer [abstract]. Am Soc Clin Oncol 1997;16:460.
38. Delmas PD, Balena R, Confraveux E. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997;15:955-62.
39. Wronski TJ, Dann LM, Qi H, Yen SF. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomised rats. Calcif Tissue Int 1993;53:210-6.
40. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumours. N Engl J Med 1989;320:479-84.
41. Turken S, Siris E, Seldine D, Flaster E, Human G, Lindsay R. Effects oftamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst1989;81:1086-8.
42. Powles TJ, Muindi J, Coombes C. Mechanisms for development of bone metastases and effects of anti-inflammatory drugs. In: Powles TJ, editor. Prostaglandins and cancer: first international conference. Alan R. Liss, 1982:541-3.
43. Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80(Suppl 8):1546-56.
44. Siwek B, Lacroix M, DePllak C, Marie P, Body JJ. Secretory products of breast cancer cells specifically affect human osteoblastic cells: partial characterization of active factors. J Bone Miner Res 1997;12:552-60.
45. Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993;34:1039-44.
46. Macro M, Bouvard G, LeGangneux E, Colin T, Loyau G. Intravenous aminohydroxy-propylidine bisphosphonate does not modify 99m Tc-hydroxymethylene bisphosphonate bone scintigraphy: a prospective study. Rev Rheum Engl Ed 1995;62:99-104.
47. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478-87.
48. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-33.
49. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996;18:9-14.
50. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide independent mechanism. J Bone Miner Res 1996;11:1482-91.
51. Krempien B. Morphological findings in bone metastasis, tumorosteopathy and anti-osteolytic therapy. In: Diel IJ, Kaufmann M, Bastert G, editors. Metastatic bone disease: fundamental and clinical aspects. Springer, 1994.
52. Yoneda T, Sasaki A, Mundy G. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994;32:72-84.
53. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowek C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
54. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast cancer call adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890-4.
55. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, et al. MMP inhibition and down regulation by bisphosphonates. Ann N Y Acad Sci 1999;878:453-65.
56. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341-7.
57. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-7.
58. van Holten-Verzantvoort AT, Hermans J, Beex LV, Blijham G, Cleton FJ, van Eck-Smit BC, et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients? Eur J Cancer 1996;32A:450-4.
59. Diel I, Solomeyer EP, Costa S, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
60. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88: 1652-8.
61. Saarto T, Blomqvist C, Virkunen P, et al. No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients. Proc Am Soc Clin Oncol 1999;18:Abstract 48.
62. Powles TJ, Paterson AHG, Neventaus S, et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Proc Am Soc Clin Oncol 1998;17:Abstract 468.